Our collaboration with BioWorld Today

In line with our mission to bring only the most critical news and analysis to biotechnology readers like yourself, we've partnered with our friends at BioWorld Today on a special two-part editorial series. Part I runs today; John Carroll introduces it in the space above. Catch Part II in FierceBiotech on March 19, and a second-two part series follows in FiercePharma.

Drop me a line if you have ideas on how we can best continue satisfying your daily diet of biotech news on email, Twitter, or LinkedIn, and most of all--thanks for your readership. – Arsalan Arif, publisher

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.